Gilead invests $5.1bn in Belgian biotech GalapagosBelgian biotech Galapagos has signed a shiny new deal with Gilead to develop inflammatory disease and rheumatoid arthritis Share XGilead invests $5.1bn in Belgian biotech Galapagoshttps://pharmaphorum.com/news/gilead-invests-5-1bn-in-belgian-biotech-galapagos/
The future of clinical trials innovationMedidata is engaging with regulators to advise on the future of clinical trials, but CEO Tarek Sherif cautions Share XThe future of clinical trials innovationhttps://pharmaphorum.com/r-d/views-analysis-r-d/the-future-of-clinical-trials-innovation/
Novartis trims again with $390m drugs sale to RecordatiNovartis has been streamlining its business since CEO Vas Narasimhan took over, and has continued that push with Share XNovartis trims again with $390m drugs sale to Recordatihttps://pharmaphorum.com/news/novartis-trims-again-with-390m-drugs-sale-to-recordati/
Novartis and Amgen axe BACE drug for Alzheimer’sAnother Alzheimer’s disease drug has been axed after Novartis, Amgen and the Banner Alzheimer’s Institute decided to end Share XNovartis and Amgen axe BACE drug for Alzheimer’shttps://pharmaphorum.com/news/novartis-and-amgen-axe-bace-drug-for-alzheimers/
The importance of pharma CSRThe industry is increasingly aware of the importance of corporate social responsibility (CSR) programmes – and Alex Kalomparis, Share XThe importance of pharma CSRhttps://pharmaphorum.com/r-d/views-analysis-r-d/the-importance-of-pharma-csr/
FDA fast tracks Prevail’s Parkinson’s gene therapyThe FDA has fast tracked a gene therapy for a certain form of Parkinson’s Disease from US biotech Share XFDA fast tracks Prevail’s Parkinson’s gene therapyhttps://pharmaphorum.com/news/fda-fast-tracks-prevails-parkinsons-gene-therapy/
The Latest Innovations in HPAPI Manufacturing TechnologiesHPAPI Technologies Share XThe Latest Innovations in HPAPI Manufacturing Technologieshttps://pharmaphorum.com/partner-content/the-latest-innovations-in-hpapi-manufacturing-technologies/
ViiV hails data showing switch from Truvada to two-drug HIV regimenViiV is continuing its assault on arch-rival Gilead in HIV, with phase 3 results aimed at giving doctors Share XViiV hails data showing switch from Truvada to two-drug HIV regimenhttps://pharmaphorum.com/news/viiv-hails-data-showing-switch-from-truvada-to-two-drug-hiv-regimen/
Bayer/J&J eye new paediatric use for anticoagulant XareltoBayer and Johnson & Johnson’s Xarelto (rivaroxaban) has been shown to prevent recurrence of thromboembolism in children, paving Share XBayer/J&J eye new paediatric use for anticoagulant Xareltohttps://pharmaphorum.com/news/bayer-jj-eye-new-paediatric-use-for-anticoagulant-xarelto/
